Inventiva SA, a clinical-stage biopharmaceutical company, has reported its preliminary financial results for the first half of 2025. The company's revenues for this period reached €4.5 million, a notable increase compared to no revenues generated in the same period in 2024. This revenue was primarily driven by a $10 million (€8.6 million) milestone payment invoiced to CTTQ and $5 million (€4.3 million) credit notes recognized under a license agreement with CTTQ. As of June 30, 2025, Inventiva reported cash and cash equivalents totaling €122.1 million and short-term deposits of €24.6 million. This represents an increase from the €96.6 million in cash and cash equivalents as of December 31, 2024. The company experienced a negative exchange rate effect on cash and cash equivalents of (€1.0) million during the first half of 2025, contrasting with a positive €0.1 million effect in the same period of 2024, due to changes in the EUR/USD exchange rate. Net cash used in operating activities increased to (€53.9) million, compared to (€48.3) million for the first half of 2024, mainly due to working capital changes and the impact of the company's pipeline prioritization plan. Research and development expenses remained stable at (€45.2) million. Net cash used in investing activities was (€24.8) million, a shift from €8.9 million generated in the first half of 2024, primarily due to new deposit subscriptions. The company expects the receipt of the $10 million milestone payment from CTTQ in July 2025 to impact cash flow in the second half of the year. The next financial results publication is scheduled for September 29, 2025, after the U.S. market close.